35 related articles for article (PubMed ID: 15182177)
1. Rapid identification of improved protein ligands using peptoid microarrays.
Lim HS; Reddy MM; Xiao X; Wilson J; Wilson R; Connell S; Kodadek T
Bioorg Med Chem Lett; 2009 Jul; 19(14):3866-9. PubMed ID: 19380225
[TBL] [Abstract][Full Text] [Related]
2. Peptoid ligands that bind selectively to phosphoproteins.
Cai D; Lee AY; Chiang CM; Kodadek T
Bioorg Med Chem Lett; 2011 Sep; 21(17):4960-4. PubMed ID: 21742492
[TBL] [Abstract][Full Text] [Related]
3. Molecular Dynamics model of peptide-protein conjugation: case study of covalent complex between Sos1 peptide and N-terminal SH3 domain from Grb2.
Luzik DA; Rogacheva ON; Izmailov SA; Indeykina MI; Kononikhin AS; Skrynnikov NR
Sci Rep; 2019 Dec; 9(1):20219. PubMed ID: 31882608
[TBL] [Abstract][Full Text] [Related]
4. Regions outside of conserved PxxPxR motifs drive the high affinity interaction of GRB2 with SH3 domain ligands.
Bartelt RR; Light J; Vacaflores A; Butcher A; Pandian M; Nash P; Houtman JC
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2560-9. PubMed ID: 26079855
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.
Qu Y; Chen Q; Lai X; Zhu C; Chen C; Zhao X; Deng R; Xu M; Yuan H; Wang Y; Yu J; Huang J
Mol Cancer; 2014 Apr; 13():95. PubMed ID: 24775912
[TBL] [Abstract][Full Text] [Related]
6. Grb2 signaling in cell motility and cancer.
Giubellino A; Burke TR; Bottaro DP
Expert Opin Ther Targets; 2008 Aug; 12(8):1021-33. PubMed ID: 18620523
[TBL] [Abstract][Full Text] [Related]
7. Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.
Gril B; Vidal M; Assayag F; Poupon MF; Liu WQ; Garbay C
Int J Cancer; 2007 Jul; 121(2):407-15. PubMed ID: 17372910
[TBL] [Abstract][Full Text] [Related]
8. Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains.
Zhou HX
Biophys J; 2006 Nov; 91(9):3170-81. PubMed ID: 16891373
[TBL] [Abstract][Full Text] [Related]
9. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
10. Peptoid architectures: elaboration, actuation, and application.
Yoo B; Kirshenbaum K
Curr Opin Chem Biol; 2008 Dec; 12(6):714-21. PubMed ID: 18786652
[TBL] [Abstract][Full Text] [Related]
11. Design of peptoid analogue dimers and measure of their affinity for Grb2 SH3 domains.
Vidal M; Liu WQ; Lenoir C; Salzmann J; Gresh N; Garbay C
Biochemistry; 2004 Jun; 43(23):7336-44. PubMed ID: 15182177
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular analysis of Grb2 SH3 domain mutants: interaction with Sos and dynamin.
Vidal M; Goudreau N; Cornille F; Cussac D; Gincel E; Garbay C
J Mol Biol; 1999 Jul; 290(3):717-30. PubMed ID: 10395825
[TBL] [Abstract][Full Text] [Related]
13. The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif.
Lewitzky M; Kardinal C; Gehring NH; Schmidt EK; Konkol B; Eulitz M; Birchmeier W; Schaeper U; Feller SM
Oncogene; 2001 Mar; 20(9):1052-62. PubMed ID: 11314042
[TBL] [Abstract][Full Text] [Related]
14. High affinity Grb2-SH3 domain ligand incorporating Cbeta-substituted prolines in a Sos-derived decapeptide.
Jacquot Y; Broutin I; Miclet E; Nicaise M; Lequin O; Goasdoué N; Joss C; Karoyan P; Desmadril M; Ducruix A; Lavielle S
Bioorg Med Chem; 2007 Feb; 15(3):1439-47. PubMed ID: 17113302
[TBL] [Abstract][Full Text] [Related]
15. Solution structure of Grb2 reveals extensive flexibility necessary for target recognition.
Yuzawa S; Yokochi M; Hatanaka H; Ogura K; Kataoka M; Miura K; Mandiyan V; Schlessinger J; Inagaki F
J Mol Biol; 2001 Feb; 306(3):527-37. PubMed ID: 11178911
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
